quantisnow
FeedTopReportsPricing
⌘K
Live feed
02:30:00·25d
PRRelease
Nanobiotix S.A. logo

NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer

NBTX· Nanobiotix S.A.
Health Care
Original source

Companies

  • NBTX
    Nanobiotix S.A.
    Health Care

Recent analyst ratings

  • Feb 6UpdateTD Cowen-
  • Aug 28UpdateGuggenheim$12.00
  • Dec 8UpdateLeerink Partners$11.00

Related

  • SEC4d
    SEC Form 6-K filed by Nanobiotix S.A.
  • PR4d
    Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
  • SEC16d
    SEC Form 6-K filed by Nanobiotix S.A.
  • SEC23d
    SEC Form 6-K filed by Nanobiotix S.A.
  • SEC23d
    SEC Form 20-F filed by Nanobiotix S.A.
  • PR23d
    NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results
  • SEC25d
    SEC Form 6-K filed by Nanobiotix S.A.
  • SEC28d
    SEC Form 6-K filed by Nanobiotix S.A.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022